Clinical Trial Update: Study of NNZ-2566 in Patients With Traumatic Brain Injury [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of NNZ-2566 for traumatic brain injury has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Injuries

Drugs mentioned

• NNZ-2566

Snippet

Sponsor: Neuren Pharmaceuticals Limited | Conditions: Brain Injuries | Phase 2 | Status: COMPLETED